| P2093 | author name string | Y Ma | |
| | C Cui | |
| | P Lal | |
| | Z Bing | |
| | S Master | |
| | T Baradet | |
| P2860 | cites work | Parafibromin expression in lung normal tissue and carcinoma: its comparison with clinicopathological parameters of carcinoma | Q39520888 |
| | Parafibromin expression is an independent prognostic factor for colorectal carcinomas | Q39593738 |
| | Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function | Q40168423 |
| | Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma | Q40505781 |
| | SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver | Q41908225 |
| | Immunohistochemical assessment of parafibromin in mouse and human tissues | Q48363314 |
| | Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. | Q50986860 |
| | Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? | Q61885121 |
| | HRPT2 gene alterations in ossifying fibroma of the jaws | Q61934970 |
| | Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene | Q79387201 |
| | Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias | Q80165778 |
| | Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism | Q81893473 |
| | Parafibromin inhibits cancer cell growth and causes G1 phase arrest | Q24304063 |
| | Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo | Q24319343 |
| | The parafibromin tumor suppressor protein is part of a human Paf1 complex | Q24557571 |
| | Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31 | Q24672747 |
| | Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice | Q28592704 |
| | Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression | Q33209570 |
| | Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma | Q33907163 |
| | HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome | Q34159232 |
| | Somatic and Germ-Line Mutations of theHRPT2Gene in Sporadic Parathyroid Carcinoma | Q34273263 |
| | Renal neoplasia in the hyperparathyroidism-jaw tumor syndrome | Q35972332 |
| | HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome | Q36185320 |
| | Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation | Q36382995 |
| | Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas | Q36444814 |
| | Human RNA polymerase II-associated factor complex: dysregulation in cancer. | Q36864019 |
| | Parafibromin--functional insights | Q37517704 |
| | Clinical genomics of renal epithelial tumors | Q37901793 |
| | Parafibromin expression in breast cancer: a novel marker for prognostication? | Q38432689 |
| P433 | issue | 4 | |
| P304 | page(s) | e39 | |
| P577 | publication date | 2012-10-23 | |
| P1433 | published in | European Journal of Histochemistry | Q2192188 |
| P1476 | title | Expression of parafibromin in major renal cell tumors | |
| P478 | volume | 56 | |